Skyrizi benefit will be expanded from next month

to Psoriasis Arthritis

Ministry of Health and Welfare Administration Announcement

Reva-K ·Reba-eye's benefit standard newly established

Expanded standards for oral hepatitis B drugs.

 

From March 1, the scope of recognition of drug care benefits by Skyrizi PFS is expected to expand from existing psoriasis to active and progressive psoriatic arthritis.

 

Reva-K and Reba-eye 2% are listed as new benefits, and medical benefits are recognized when administered to "improve corneal epithelial disorders in adult ocular anterior patients." The criteria for recognition of medical care benefits for oral chronic hepatitis B treatment will also be expanded compared to the previous one.

 

The phrase of the Argatroban component injection is changed so that the detailed recognition criteria for medical care benefits are administered within the scope of permits for each drug.

 

The hemostatic oxidative regenerative cellulose benefit item is changed from Equtamp to Surgicel.

 

On the 15th, the Ministry of Health and Welfare will announce the administrative notice of "partial revision of the criteria and methods for applying for medical care benefits" and conduct a related opinion inquiry until the 24th.

 

First, the standard of the AbbVie interleukin (IL)-23 inhibitor Skyrizi PFS will be expanded.

 

Skyrizi, which is an indication of plate psoriasis and psoriatic arthritis, is currently only reimbursed for psoriasis.

 

The Ministry of Health and Welfare adds 'active and progressive psoriatic arthritis' to the Skyrizi standard.

 

Skyrich will also be added to the replacement pay standard for Tremfya, Taltz PFS, Cosentyx, and Stelara.

 

2% Reva-K and Reba-ye, are newly registered and a new standard will be established.

 

Nursing benefits are recognized if administered within the scope of the permit, "Improvement of corneal epithelial disorders in adult dry eye patients." However, benefits are not recognized when administered in combination with mucin secretion promoters such as Diquasol Eye drops.

 

Oral chronic hepatitis B drugs expand the liver enzyme (AST/ALT) numerical standard that recognizes drug benefits.

 

The HBV-DNA numerical standard, which recognizes benefits even in chronic hepatitis B patients accompanied by targeted cirrhosis, is expanded.

 

Specifically, "Patients with 40-80 units of AST or ALT and showing stages of liver biopsy or fibrosis of illiterate periphery" will be added to the initial treatment benefit standard.

 

Patients with chronic active hepatitis B with cirrhosis and hepatocellular carcinoma are recognized for benefits if they are HBV-DNA positive.

 

The standard item of Agastroban injection, an antithrombotic component used to treat chronic arterial obstruction, will be revised from "Argaron Inj" to "Argaron Inj, etc." Considering that each drug has different permits, the statement of the administration discussion will be changed within the scope of each drug.

 

The standard item for hemostatic oxidatively regenerated cellulose is changed from Equtamp to Surgicel.

 

This is to make it current as an item on the list of drug benefits.